Pentoxifylline Therapy: A New Adjunct in the Treatment of Pulmonary Hypertension?

AUTOR(ES)

Park, In-Sook

RESUMO

Patients with markedly elevated pulmonary vascular resistance, whether caused by primary pulmonary hypertension or by congenital heart disease, have a grave prognosis, regardless of the type of therapy they undergo. This brief report presents our experience in treating 6 patients (4 women and 2 men) having pulmonary vascular obstructive disease, by administrating pentoxifylline (Trental), a drug that has been used in patients with chronic occlusive systemic arterial disease. Our patients underwent treadmill testing before the study and again 1 to 3 months after initiation of the study. Duration of exercise was short in all patients; however, it increased significantly while patients were taking pentoxifylline. These preliminary results are encouraging; however, we were unable to confirm other physiologic improvement with noninvasive study, and placebo effect was not ruled out. Therefore, we believe that use of pentoxifylline in patients with pulmonary vascular obstructive disease warrants further investigation by means of detailed direct hemodynamic measurement. (Texas Heart Institute Journal 1988;15:163-165)

Documentos Relacionados

• Is Patient Education about the Benefits of Physical Activity a Good Adjunct Treatment Strategy in Hypertension?
• Photodynamic therapy: a new concept in medical treatment
• Tienilic acid: a single treatment for hyperuricaemia and hypertension?
• Somatic cell gene therapy for a trait as complex as hypertension?
• Genetic therapy: on the brink of a new future